Daisuke Ishikawa

Title: Daisuke Ishikawa: Innovator in Integrin Antibody Research

Introduction

Daisuke Ishikawa is a prominent inventor based in Kumamoto, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of integrin antibodies. With a total of two patents to his name, Ishikawa's work focuses on innovative solutions for medical treatments.

Latest Patents

Ishikawa's latest patents include a human anti-α9 integrin antibody and a humanized anti-human α9 integrin antibody. The first patent provides a human anti-α9 integrin antibody or an antibody fragment that specifically recognizes human and mouse α9 integrin. This invention inhibits the interaction with their ligands and includes a gene encoding the antibody, a recombinant expression vector, and a production method for the antibody or fragment. The second patent presents a humanized anti-human α9 integrin antibody that has improved activity compared to a donor mouse anti-human α9 integrin antibody. This invention also outlines various amino acid sequences and their applications in treating diseases involving human α9 integrin.

Career Highlights

Throughout his career, Daisuke Ishikawa has worked with notable organizations such as the Juridical Foundation the Chemo-Sero-Therapeutic Research Institute and Astellas Pharma GmbH. His experience in these institutions has allowed him to advance his research and contribute to the field of antibody development.

Collaborations

Ishikawa has collaborated with esteemed colleagues, including Toshihiro Nakashima and Hirofumi Higuchi. These partnerships have fostered innovation and have been instrumental in his research endeavors.

Conclusion

Daisuke Ishikawa's work in the field of integrin antibodies showcases his dedication to advancing medical science. His patents reflect a commitment to developing effective treatments for various diseases. Through his career and collaborations, Ishikawa continues to make a significant impact in biotechnology.